{"name":"Korean Gynecologic Oncology Group","slug":"korean-gynecologic-oncology-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE4xb29JRFNhWlZ4Z2JJcGkyZHh1STN2LVVaai1hSm12Xy1HTFU0dXBSMjhSbWVPaWNEQ0c1OElsYkl0S1pMX2dFM250S2l5M0lLczAzWEJUUzV0cDRIRWFabGtLSjZiNDdaWjFyMVhB0gFyQVVfeXFMT1lzdUpUQ0lzeHY0UllKR2F0akRSejFxVWVCdk8zTGZBenpzSGtmNUhfSV9fU0Q5NS12LU03dEwzeE85Mk9TQ0dZa0ZLZ1Y0cloyYTBtYm4zcGJMSmpKdHkwWmNVSUhJczc1UUhRaFA4TWFR?oc=5","date":"2026-03-06","type":"pipeline","source":"koreabiomed.com","summary":"‘If obstetrics collapses, Korea has no future’ - koreabiomed.com","headline":"‘If obstetrics collapses, Korea has no future’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFAwcXQxWjhJbUJNSUl3dGd0c2NUdHE3NWlZU0NmSS0yZkdmOVRiQmJic1haeEVRNjVqZUpDUnlmZzYtLVFXYTlMMEJ5SVNubTJYMmVZdDZ2bmZzcE91YUVvRTdxS215enBsanE4OC1R0gFyQVVfeXFMTkFJMV9aRGlsTl9yd0R6bjBNLUVxalN6UEFwTzFuUVhTWHc0VGtUNUplbzZ0MV9qV24yalhYR2gtQmZzZU5HQmxucTllMzhMSW5vLXllb0xwMXVLVVpTUVBoSV82UGd3Z3VEa00wNTVXaVd3?oc=5","date":"2026-02-27","type":"pipeline","source":"koreabiomed.com","summary":"PARP inhibitor–bevacizumab combo extends survival in recurrent ovarian cancer - koreabiomed.com","headline":"PARP inhibitor–bevacizumab combo extends survival in recurrent ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE12OWF3dU8xS20xWEhvQjJYMkR4aFNLVGlwRGI2Ym9hY0VoTGpZbkRpbHZKZ0J1VlpmZGNyS2pKdHZiakFySkpkS1p5Si03RTBRTmQ3Wlh4YnBRZ0dOZFNpTjA3SGM2S1RRYXA3TDhB0gFyQVVfeXFMUFpzemgxNFotN2YwbGNHZC04cTZ5QVVGWmZBRXpWVDZGeFhoOFlQUjBWM1F0YnFQV0ZLaGVDVW9aRl9LeVQyTzhVSGhBZXpwZFI0MVdjNXZoaWJpNFlQRG9RcURfM2NnaDdoR2w0MDJHd21n?oc=5","date":"2026-01-28","type":"pipeline","source":"koreabiomed.com","summary":"AbbVie’s Elahere launches in Korea, marking 1st ADC for ovarian cancer - koreabiomed.com","headline":"AbbVie’s Elahere launches in Korea, marking 1st ADC for ovarian cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBBU1A5ejF6Mnd5bkEzNTZSazcwYnNCckpvNEo4T0ZIUUpPWl8zc1EzM0dFOE5MMUxmLWZybmZ6N09FdVBxaXZZM0VQcW5ES1hfazhHNmtfY09rWmo5N0daQ3E5d1I2UE5pckV4ZHBB0gFyQVVfeXFMTl9fMTEzdlhVVVdnVGtncVFVSGRTZ3BGWm9DX3FaMzdzT1NaRHpPOHQxRHc3X04yQ3JuR0hoMmx1Wk5sbEdzY2hQSmhvTEQ1OVB3bDNyWjFXb0dNc3VJTXN3UHlMMWpwQTEzMlZfaGpOV0l3?oc=5","date":"2025-12-24","type":"pipeline","source":"koreabiomed.com","summary":"Korea to expand Keytruda reimbursement to 11 new cancer uses starting 2026 - koreabiomed.com","headline":"Korea to expand Keytruda reimbursement to 11 new cancer uses starting 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1sbUp0c3pUWmpONmNvR0dGaDRmNk1WbG1CYjJWUndhR242bnVtdjVtR1pLMGtYYkg5UU9nR00xUEJGTzJSTGhQZ2I4RkE1QlcyMkFrUHlxTjgzVFRKSzVFbmJoVkstb19KOGRwWEVB0gFyQVVfeXFMTXZhWktpc0hSMWRndDBKbFNTZzAzUXl2QjFZTC1BdVZLQ1hIR1J5aGtZQ05yeGdJbzNYUFRxNWdGVU1XUDd5Ql9PVjJHTjRaaVVIMlRaNUJtd3dHa2hNYXZhWl9teW5hdjhLUUJPdlhULVVB?oc=5","date":"2025-12-22","type":"regulatory","source":"koreabiomed.com","summary":"AbbVie’s Elahere wins Korean approval for platinum-resistant ovarian cancer - koreabiomed.com","headline":"AbbVie’s Elahere wins Korean approval for platinum-resistant ovarian cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPUEZCd2N6TDNqc0VodDFrekktY2g1YnIxZnItSmFIbHBndmNOb2xvaEdDUzZYS2JkZ3VIbVRnMF9tb0FfVURtQ2JNUG40RW9JTDZwQWhid2NLUmRCNE1zTUFaN1l0c29xVVN6SVM1SGtiSURVbnhqMTBwVFp4Z292SNIBlAFBVV95cUxOVWRCSm5rVUFYWW4yd0ZZb0xKaXhGTHhmeDRJbHJzY2NTUXBSclhGQTBFam8xV3ZKNHZfVVh2RGoxRjNLTTNQU2RiVUZVNENVWGx2Rm1VM01kWGJ4UXNsTkpPYWFRVEhpTUdrcEpYcUo0Y3h3VDh5RlpUNjh0UWRnYlBWb1F3S21KZC1ZeFRRTW0xY0sz?oc=5","date":"2025-08-09","type":"pipeline","source":"Chosunbiz","summary":"Obesity drug launch faces delays in South Korea due to outdated pharmacy regulations - CHOSUNBIZ - Chosunbiz","headline":"Obesity drug launch faces delays in South Korea due to outdated pharmacy regulations - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5YNmhpaU5BbDk3cjhDR3EwTEl1MWtpRlFDSEZyWDJlQXVaRHc3SUFQT0IxTWZRSWFqQUdBNlVFSmpuZXUtdm5lbzZrUElkeFIwSzF0eE9zXzZJYkZ3LW0temIzR3FrN1dnQVJJNFBR0gFyQVVfeXFMTXBTV2NtRWhydUs3VGVBZlRfNlBydE5tWlY3NTBKMHZqUWhydV96TXZyX3dwdU9hdVdiUXEwRi1QUE9vOWhaaXRCa3h2MkItWWczRl9LVXNxLWEtVHRZVmJucm1RUEhZRjJhYUpVbkM0VUp3?oc=5","date":"2025-06-25","type":"trial","source":"koreabiomed.com","summary":"AZ redefines endometrial and ovarian cancer playbook - koreabiomed.com","headline":"AZ redefines endometrial and ovarian cancer playbook","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1xdzMweDFabXh5TXc2Vlk2ckFKMGpQbFg3cUt4U1B6ay03Y3lEcS1UQXhvU3NRWFh4TlU1dG1lRV9vS0FQTG5qVXZmWThIVTNqRlpMWjZLM0ZUWHFReFJOWER6TzFPOTBiRzZEcmhn0gFyQVVfeXFMUDRpRVdKT1NrbVhWSTJpQ3pyVkdSQVhoYVcxQklKdHR0OHA0SEZOdWhnX3V1Z0U0aE5mLXQ5RHA2WmZTMlRLUTRibHJsT1hkWlNXamFqMFVSMEhXQUVrRzJKa1NaR3dCME1JVldudkhCeGZR?oc=5","date":"2024-12-10","type":"trial","source":"koreabiomed.com","summary":"GSK Korea expands indication for Jemperli in endometrial cancer treatment - koreabiomed.com","headline":"GSK Korea expands indication for Jemperli in endometrial cancer treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9PRWZPeWFyb1ZrT01KQ3FpdEgtWXRRSkFQdlR5a1R1TmpDY3VFSEd2aGdsSFJVcXo1bHhXVWtlWm1DbGFvbEpNSml3a2Y3TVBRTEQ0ZUJ0d1NEQ3BiZG9zTFlyb2VsTDBGUmRWVlZR?oc=5","date":"2024-08-19","type":"pipeline","source":"KED Global","summary":"CHA Healthcare incorporates Singapore's SMG as subsidiary - KED Global","headline":"CHA Healthcare incorporates Singapore's SMG as subsidiary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1JbllHUGl5MHUzV3FXWklycnBRYkNHd1F6UTR0dHhMeXBIa1JuUWlqTkFCMzFPTnNaUUhmM3dMS2k2dFRpTUFmNUpRank2bElacW9odkJDMW1wckF5MWpr?oc=5","date":"2020-09-30","type":"regulatory","source":"nature.com","summary":"A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer - nature.com","headline":"A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-11-28","type":"pipeline","source":"The Korea Times","summary":"[INTERVIEW] 50 years on, Yonsei Cancer Center continues pioneering path - The Korea Times","headline":"[INTERVIEW] 50 years on, Yonsei Cancer Center continues pioneering path","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBaSmtudllPTWlXTWQ5RERMLVJYVVRVWkN4RTBjd2pGdFBpbF8xNm40RGtxMUhoOERKZmpraFF3eE9hNDZuaHVLbnBvd3NfU01UbHE5QWszelhOYzFENENzQw?oc=5","date":"2019-02-27","type":"trial","source":"NEJM","summary":"A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms - NEJM","headline":"A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}